Novel molecule for Adjuvant Therapy for Sepsis

- **TECHNOLOGY**: After infection, sepsis manifests usually as an over-drive of the innate immune response towards gram negative bacterial toxins such as LPS. The cytokine storm seriously shortens the patient's survival window for traditional antibiotics to take hold of the infection. The current technology comprises a potent immunomodulator derived from a recombinant helminth protein that binds to Toll like receptors (TLR) and thus blocks interaction of the TLRs with LPS like toxins resulting in down-regulation of the immune flare-up.

- **DOMAIN**: Novel Molecules for Disease Intervention

- **ADVANTAGES**: Most existing interventions for sepsis are found to be effective only if provided at very early time points after the onset of sepsis. The current technology allows for a broad window for administering targeted interventions for sepsis. Excellent results in terms of survival were obtained both in endotoxemia model as well as caecal ligation and puncture models of sepsis.

- **IP STATUS**: PCT/IB/ 2020/062459 filed in Dec 2020 and nationalized in India, Indonesia, Brazil, USA, S.Korea, S.Africa, Australia, Europe and New Zealand

Contact us:

OFFICE OF TECHNOLOGY TRANSFER, CENTRE FOR CELLULAR AND MOLECULAR PLATFORMS (C-CAMP). GKVK POST, BELLARY ROAD,. BANGALORE 560065, INDIA.
EMAIL: OTT@CCAMP.RES.IN, PH: +918067185322